ADVERTISEMENT

Lupin Gets U.S. FDA Nod For Formoterol Fumarate Inhalation Solution

Lupin's new offering can be used in treating symptoms of chronic obstructive pulmonary disease.

<div class="paragraphs"><p>Lupin's manufacturing facility in Goa. (Photo: Company website)</p></div>
Lupin's manufacturing facility in Goa. (Photo: Company website)

Lupin on Wednesday said it has received approval from the U.S. FDA for Formoterol Fumarate Inhalation Solution, used in treating symptoms of chronic obstructive pulmonary disease.

The company has received approval from the U.S. Food and Drug Administration for the product which is a generic version of Mylan Specialty's Perforomist Inhalation Solution, the Mumbai-based drug maker said in a statement.

As per IQVIA MAT June 2022 data, the medication had annual sales of around $282 million in the U.S. market.

Shares of Lupin ended 2.55% down at Rs 677.65 apiece on the BSE on Wednesday.